Keyword: NGM Biopharmaceuticals
NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.
NGM Bio’s aldafermin is an engineered version of the hormone FGF19, which modulates two receptors: FGFR4, which regulates bile acid synthesis in the liver, and FGFR1c, a signaling receptor in body fat that regulates the creation of new fats, glucose management and body weight.
From Big Pharmas like Novartis and Gilead to liver specialists and one-asset biotechs, it seems like everyone in biopharma has some skin in the NASH game. This report examines the top prospects in the NASH pipeline, and why we even need a drug for nonalcoholic steatohepatitis in the first place.
Expectations for NASH are still sky-high—some see billions for any drug that gets it right at peak—but the reality of clinical trials has been murky.
NGM presented data showing that its once-monthly nonalcoholic steatohepatitis drug improved insulin sensitivity in people with diabetes.
Fatty liver disease biotech NGM Bio has got off a $107 million IPO, following in the footsteps of rival GenFit.
NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.
Merck is extending its 2015 R&D pact with NGM Bio for a broad range of early-stage assets. It's also culling one therapy that didn't work out.
The agreement gives Merck control of a drug designed to reduce liver fat content by selectively activating FGFR1c.